Dry suspension granules for dry suspension, including the dry suspension made of the said dry suspension granules, and preparation method thereof are provided. Such-The dry suspension granules contain anionic gel and cationic polymer. The weight ratio of the anionic gel and the cationic polymer is (0.5-50):1.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C08J 3/00 - Processes of treating or compounding macromolecular substances
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (China)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (China)
Inventor
Ding, Ke
Chinnaiyan, Arul M.
Li, Chungen
Wang, Zhen
Qiao, Yuanyuan
Abstract
A PIKfyve protein degradation agent and the use thereof. Specifically, provided is a compound having the structure as represented by formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can target and degrade the PIKfyve protein by means of the ubiquitin-proteasome pathway, and therefore the compound can be used for treating indications mediated by the abnormal expression of the PIKfyve protein.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
A crystal form A of a compound shown in formula I is prepared for the first time in the present invention. The form has important significance for improving the characteristics such as drug production, quality control, and solid oral preparation development prospects. The physical and chemical stability evaluation result shows that the crystal form A is a hydrate and does not lose water and does not have hygroscopicity under conventional conditions; moreover, the stability is obviously superior to that of an amorphous form and a crystal form E under high temperature, high humidity, acceleration experiments and illumination experiments. Furthermore, the fluidity of the crystal form A is superior to that of the crystal form E and the amorphous form. Finally, the bioavailability of the crystal form A is obviously higher than that of the amorphous form. On the basis of good physical and chemical stability, fluidity and bioavailability of the crystal form A, the crystal form A has great potential in subsequent development and production.
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (China)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (China)
Inventor
Ding, Ke
Chinnaiyan, Arul M.
Yang, Jianzhang
Chang, Yu
Zhou, Licheng
Zhou, Kaijie
Wang, George Xiaoju
Wang, Zhen
Huang, Weixue
Zhou, Fengtao
Abstract
The present invention relates to an aryl substituent-containing degradation agent for cyclin-dependent kinase 12/13 (CDK12/13), a preparation method therefor, and a pharmaceutical composition and use thereof. The degradation agent for CDK12/13 of the present invention has a structure represented by formula (I). The compound can be used as a protein kinase degradation agent, and can effectively and highly selectively degrade a CDK12/13 protein and inhibit proliferation, migration, and invasion of various tumor cells.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (China)
LIVZON PHARMACEUTICAL GROUP INC. (China)
Inventor
Ding, Ke
Lei, Chong
Liu, Rong
Wang, Yongxing
Huang, Weixue
Lu, Xuzhi
Abstract
Provided in the present invention are a compound having a skeleton structure as represented by formula (I) or a pharmaceutically acceptable salt, an isotope derivative and a solvate thereof, or a stereoisomer, a geometric isomer and a tautomer thereof, or a prodrug molecule, a metabolite and a pharmaceutical composition thereof, and the use thereof. The compound involved in the present invention can efficiently inhibit the kinase activity of HPK1, has a relatively strong signal inhibition effect on a downstream pathway thereof, can be used for preparing an anti-tumor drug, and can also be used for preparing a drug for preventing and treating inflammatory diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
An enteric-coated pellet, a method for preparing the same and a formulation comprising the same are provided. The enteric-coated pellet can be an ilaprazole enteric-coated pellet.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
7.
USE OF ILAPRAZOLE IN REGULATING INTESTINAL MICROECOLOGY
The present invention relates to use of ilaprazole or a pharmaceutically acceptable salt thereof in regulating intestinal microecology, particularly in regulating the abundance of Bacteroidota bacteria and Bacillota bacteria, and also relates to use of ilaprazole in reducing the risk of pulmonary infection and regulating gastric microecology and serum gastrin. Ilaprazole is especially beneficial to the treatment of Helicobacter pylori, and is more suitable for an individual in need of long-term medication, such as a patient with a gastroesophageal reflux disease.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
8.
DRY SUSPENSION PARTICLES FOR DRY SUSPENSION, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to dry suspension particles used for dry suspension, dry suspension containing the dry suspension particles, a preparation method therefor and a use thereof. The dry suspension particles comprise an anionic gel and a cationic polymer, wherein the weight ratio of the anionic gel to the cationic polymer is (0.5~50):1.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; vaccines; biological
preparations for veterinary purposes; veterinary vaccines;
immunostimulants; biological preparations for medical
purposes; crude medicines; dietetic substances adapted for
medical use; mouthwashes for medical purposes; medicinal
tea.
10.
ENTERIC PELLET, PREPARATION METHOD THEREFOR, AND PREPARATION COMPRISING SAME
The present invention relates to an enteric pellet, a preparation method therefor, and a preparation comprising same, and particularly relates to an ilaprazole enteric pellet, a preparation method therefor, and a preparation comprising same.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; injectable pharmaceuticals;
pharmaceutical preparations for the treatment of
genitourinary diseases, namely, urological diseases,
infertility, sexually transmitted diseases, inflammatory
pelvic diseases; medicines for veterinary purposes; drug
delivery agents in the form of powders that provide
controlled release of the active ingredients for a wide
variety of pharmaceuticals; depuratives; sanitizing wipes;
pharmaceutical preparations for the treatment of hormonal
disorders; fertility enhancement preparations; estrogen
pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Diagnostic preparations for medical purposes; chemical
reagents for medical or veterinary purposes; reagent paper
for medical purposes; diagnostic biomarker reagents for
medical purposes; chemical preparations for the diagnosis of
pregnancy; antibacterial handwashes; immunostimulants;
diagnostic preparations for veterinary purposes; reagent
paper for veterinary purposes; tissues impregnated with
pharmaceutical lotions. Testing apparatus for medical purposes; medical apparatus
and instruments; apparatus for use in medical analysis;
diagnostic apparatus for medical purposes; analysers for
bacterial identification for medical purposes; apparatus for
DNA and RNA testing for medical purposes; sanitary masks for
medical purposes; blood testing apparatus.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Hormonal preparations; hormones for medical purposes; veterinary pharmaceutical preparations for the treatment of hormonal disorder of livestock; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; depuratives for the body; sanitizing wipes; pharmaceutical preparations for the treatment of hormonal disorders; fertility enhancement preparations; estrogen preparations; hormones for medical use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; drugs for medical purposes;
medical preparations for slimming purposes; food for babies;
raw material drugs; prepared Chinese medicines; antibiotics;
biochemical drugs; medical preparations for the blood;
dietetic substances adapted for medical use.
The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 μm, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Medicines for the treatment of gastrointestinal diseases, for human purposes; Pharmaceutical products for the prevention and treatment of cancer, for human purposes; Tumor suppressing agents, for human purpose; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceuticals, namely, anti-infectives; Medical preparations for slimming purposes; Food for babies; Bulk drugs, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Bulk drug in the nature of a pharmaceutical preparation for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cancer; Antibiotics; Biochemical medicines for the treatment of pneumonia, urinary tract infection, gynecological infections, skin and skin structure infections, meningitis, septicemia, cancer, diabetes, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Biochemical drugs for treatment of gastrointestinal diseases; Blood products, namely, immunoglobulins for medical or clinical use; Blood products for medical purposes, namely, blood plasma, reagent blood cells; Blood products for medical purposes, namely, blood plasma products, red blood cell products, and leukocyte products; Dietetic foods adapted for medical use; Dietetic beverages adapted for medical purposes Medical apparatus for detecting cancer; Medical device for treating cancer; Medical apparatus and instruments for use in surgery; Medical device and surgical instrument for use in diagnosis and surgery of the gastro-intestinal tract; Ultrasound diagnostic apparatus; X-ray diagnostic apparatus; Dental instruments, namely, oral irrigators; Drills for dental applications; Orthodontic machines and instruments, for dental purposes; Weight lifting machines for physical therapy; Foam rollers for use in physical therapy; Manually-operated exercise equipment for physical therapy purposes; Hearing aids; Baby bottles; Contraceptive apparatus, non-chemical; Artificial limbs; Orthopaedic belts; Orthopaedic knee bandages; Orthopaedic hip prostheses; Sanitary masks for medical purposes; Gloves for medical purposes
20.
USE OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF ANTI-ENTEROVIRUS 71 DRUG
NATIONAL ENGINEERING RESEARCH CENTER FOR MODERIZATION OF TRADITIONAL CHINESE MEDICINE (China)
Inventor
Tao, Desheng
Zeng, Yongqing
Cao, Hui
Guan, Yi
Abstract
A traditional Chinese medicine composition for preventing and treating swine influenza, preparation method and use thereof, said traditional Chinese medicine composition is prepared by using Herba Houttuyniae 21.4wt%, Caulis Lonicerae 17.9wt%, Radix Isatidis 14.3wt%, Rhizoma Osmundae 10.7wt%, Radix Sophorae Tonkinensis 7.1wt%, Radix Heraclei Scabridi 7.1wt%, Rhizoma Paridis 7.1wt%, Herba Artemisiae 7.1wt%, Rhizoma Belamcandae 7.1wt%.
Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
23.
Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof
A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %, radix angelicae dahuricae 7.1 wt. %, rhizoma paridis 7.1 wt. %, herba artemisiae annuae 7.2 wt. %, and rhizoma iridis tectoris 7.2 wt. %. This Chinese traditional medicine composition could be made into any regular medicinal types, for example, oral solutions, tablets, capsules, pellets and injection solution, etc. Modified preparation methods for this Chinese traditional medicine composition, as well as the use of the same in preparation of medicines and health foods for prevention or treatment of avian influenza were also provided in present invention. This Chinese traditional medicine composition could effectively prevent and treat avian influenza. It was a safer, more easily-obtained, and inexpensive anti-avian influenza drug.
A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %, radix angelicae dahuricae 7.1 wt. %, rhizoma paridis 7.1 wt. %, herba artemisiae annuae 7.2 wt. %, and rhizoma iridis tectoris 7.2 wt. %. This Chinese traditional medicine composition could be made into any regular medicinal types, for example, oral solutions, tablets, capsules, pellets and injection solution, etc. Modified preparation methods for this Chinese traditional medicine composition, as well as the use of the same in preparation of medicines and health foods for prevention or treatment of avian influenza were also provided in present invention. This Chinese traditional medicine composition could effectively prevent and treat avian influenza. It was a safer, more easily-obtained, and inexpensive anti-avian influenza drug.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Traditional Chinese medical compositions with effects of preventing and treating avian influenza (AI), active ingredients of which consist of Herba houttuyniae 21.4 wt.%, Caulis lonicerae 17.9 wt.%, Radix isatidis 14.3 wt.%, Rhizoma dryopteridis 10.7 wt.%, Radix sophorae 7.1 wt.%, Radix angelicae 7.1 wt.%, Rhizoma paridis 7.1 wt.%, Herba artemisiae 7.2 wt.%, Rhizoma belamcandae 7.2 wt.%. The present compositions can be made into any one of conventional dosage forms, such as oral solutions, tablets, capsules, granules and injections etc. Improved processes for preparation and usage in the manufacture of medicaments and functional foods for preventing and treating AI of the present compositions are also provided.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; drugs for medical purposes;
medical preparations for slimming purposes; food for babies;
raw material drugs; prepared Chinese medicines; antibiotics;
biochemical drugs; medical preparations for the blood;
dietetic substances adapted for medical use.
27.
SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF
Disclosed are an optically pure compound having formula (I), its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided. Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
28.
SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF
Disclosed are an optically pure compound having formula (I), its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided. Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
29.
LIVZON LIVESON Z L UVZON BEAUTIFUL PRETTY GLORIOUS JEWELRY BEAD DROP
